Phillips-Medisize enters into definitive agreement with Golden Gate Capital

NewsGuard 100/100 Score

Phillips-Medisize Corporation (the "Company") today announced that it has entered into a definitive agreement under which Golden Gate Capital will acquire the Company from funds managed by Kohlberg & Company, L.L.C. Phillips-Medisize will maintain its global headquarters in Hudson, Wisconsin, and President & CEO Matt Jennings and the current management team will remain in place. Terms of the transaction were not disclosed.

Phillips-Medisize is a leading global provider of design and manufacturing services to the pharmaceutical, medical device, diagnostic and specialty commercial markets. The Company has annual sales of approximately $600 million with 75 percent of total revenue generated from drug delivery, medical device, primary pharmaceutical packaging and diagnostic products such as disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components. Phillips-Medisize employs over 3,100 people in 19 locations throughout the United States, Europe, Mexico and China and has design centers in Wisconsin, California and the Netherlands.

"We are excited to partner with Golden Gate Capital, who is fully aligned with our long-term strategic plan and shares our deep-rooted commitment to providing customers with innovative, high-quality and cost-effective solutions with world-class service," said Matt Jennings, President & CEO of Phillips-Medisize Corporation. "Golden Gate's financial support, successful track record of backing manufacturing companies and deep industry relationships will help perpetuate the Company's strong momentum and further solidify our market-leading position. We look forward to working with our new partners as we continue to successfully execute our strategy."

"Phillips-Medisize represents a terrific opportunity to invest in a strong design and manufacturing service platform with global scale and a proven track record of delivering an exceptionally broad and deep set of capabilities to its customers," said Rajeev Amara, Managing Director at Golden Gate Capital. "The Company is well-positioned to grow and succeed in the rapidly expanding medical outsourcing market and Golden Gate Capital is committed to investing in the Company to support the next phase of its growth. We look forward to partnering with Matt and the talented Phillips-Medisize team to support their vision for the business."

"We are pleased with the outcome of our investment in Phillips-Medisize and believe that the Company has a bright future," said Chris Anderson, Partner at Kohlberg & Company. "We are confident that the Company will continue on its trajectory of success under Golden Gate Capital's ownership."

The acquisition is subject to customary regulatory approvals and is expected to close in the coming months.

Goldman, Sachs & Co acted as financial advisor to Phillips-Medisize and Ropes & Gray LLP acted as its legal counsel. Robert W Baird acted as financial advisor to Golden Gate Capital and Kirkland & Ellis LLP served as its legal counsel.

Source:

Phillips-Medisize

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities